Treating Plasma Cell Leukemia: New Insights on Bispecific Antibodies | Mahmoud Gaballa, MD

Treating Plasma Cell Leukemia: New Insights on Bispecific Antibodies | Mahmoud Gaballa, MD

Myeloma Maintenance: Daratumumab as an Alternative to Lenalidomide | Sridevi Rajeeve, MD

Myeloma Maintenance: Daratumumab as an Alternative to Lenalidomide | Sridevi Rajeeve, MD

Bispecific Therapies in Myeloma: Preferences & Priorities | Thomas LeBlanc, MD

Bispecific Therapies in Myeloma: Preferences & Priorities | Thomas LeBlanc, MD

AI Assistant for Faster, Cleaner Data | JP Capdevila

AI Assistant for Faster, Cleaner Data | JP Capdevila

Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD

Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD

Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD

Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD

REVIVE Trial : Dara + Bispecific in High-Risk Smoldering Myeloma | Ola Landgren, MD, PhD

REVIVE Trial : Dara + Bispecific in High-Risk Smoldering Myeloma | Ola Landgren, MD, PhD

New Talquetamab Combos Show Promise for Longer-Lasting Myeloma Control | Jeffrey Matous, MD

New Talquetamab Combos Show Promise for Longer-Lasting Myeloma Control | Jeffrey Matous, MD

Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD

Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD

Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD

Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD

Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD

Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD

Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD

Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD